Graeme Bell

Interim Chief Executive Officer

Graeme joined Valo as Chief Financial Officer in August 2020 and took on the role of interim CEO in January 2024. He has a distinguished 30-year career as a financial executive in the biopharmaceutical sector with a broad range of experience successfully driving strategic financial operations.

Graeme was most recently CFO at Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company in Philadelphia. Prior to Tmunity, Graeme served as CFO of Intellia where he helped to scale the then-newly public company from 80 to 250 employees, overseeing strategic operational financial functions, investor relations, IT and pre-commercial strategic planning to support their pipeline. He was also CFO at Anacor, which was acquired by Pfizer. In addition, Graeme spent over 20 years at Merck gaining extensive experience in finance and business leadership roles, not the least of which include CFO of U.S. Operations and Global Head of Investor Relations.

Graeme is a Board Director and the Chairperson of the Audit Committee for CytoImmune Therapeutics, a private clinical-stage immune-oncology company. He has also been a dedicated coach and advisor over the last several years at both the National Interscholastic Cycling Association (NICA) and Teen Trail Corp, providing young people across the country with critical opportunities to build their physical and mental capabilities through cycling while becoming active members of their communities. Graeme holds an MBA from Durham University in England.